Triple therapy aims to wipe out rectal cancer before surgery
NCT ID NCT07651007
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase II trial tests a new approach for high-risk locally advanced rectal cancer. Participants first receive short-course radiotherapy, followed by a combination of chemotherapy (NALIRIFOX) and immunotherapy (Pucotenlimab) for about 6 months. The goal is to see if this regimen can achieve a higher complete response rate and improve the chance of saving the anal sphincter, compared to historical standard treatment. The study will enroll 29 adults aged 18-70 with MSS/pMMR rectal cancer.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
short-course radiotherapy, NALIRIFOX chemotherapy, and Pucotenlimab immunotherapy
What this could lead to
If successful, this combination could offer a more effective neoadjuvant treatment for high-risk rectal cancer, potentially increasing the chance of complete tumor disappearance and avoiding permanent colostomy.
What could go wrong
This is a small, early-phase trial (29 participants) with no control group, so results may not be definitive. The combination of radiotherapy, chemotherapy, and immunotherapy may cause significant side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED RECTAL CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••